CHO-K1/Mouse D2 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0083B | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
Dopamine receptor D2 is the primary inhibitory subtype within the dopamine receptor family, belonging to the Gi/o protein-coupled receptor class. It is highly enriched in the striatum and nucleus accumbens of the brain, and widely distributed in midbrain dopaminergic neurons (as autoreceptors), the hypothalamus, and pituitary gland. Its core functions involve regulating motor coordination, inhibiting prolactin secretion, and modulating cognitive and reward circuits by suppressing cAMP signaling; it also provides negative feedback to inhibit dopamine synthesis and release in the midbrain. Consequently, the D2 receptor is a central therapeutic target for schizophrenia, Parkinson's disease (adjuvant therapy), hyperprolactinemia, and drug addiction.
Screeningbio’s CHO-K1/Mouse D2 cell line overexpress DRD2 and is designed to detect inhibition in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Mouse |
HGNC Symbol | DRD2 |
Accession Number | NM_010077 |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
Dopamine receptor D2 is the primary inhibitory subtype within the dopamine receptor family, belonging to the Gi/o protein-coupled receptor class. It is highly enriched in the striatum and nucleus accumbens of the brain, and widely distributed in midbrain dopaminergic neurons (as autoreceptors), the hypothalamus, and pituitary gland.
Its core functions involve regulating motor coordination, inhibiting prolactin secretion, and modulating cognitive and reward circuits by suppressing cAMP signaling; it also provides negative feedback to inhibit dopamine synthesis and release in the midbrain.
Consequently, the D2 receptor is a central therapeutic target for schizophrenia, Parkinson's disease (adjuvant therapy), hyperprolactinemia, and drug addiction.